Investors question durability of Boston Scientific’s electrophysiology and Watchman device growth after Q1 2026 results missed expectations.
Boston Scientific (BSX) closed at $53.06 on May 13, 2026, reflecting a 16.34% decline over the past month and a 49.40% drop over 52 weeks. The company’s $78.87 billion market capitalization faces pressure as investors debate its ability to sustain growth in key segments like electrophysiology (EP) and the Watchman left atrial appendage closure device.
The CHAMPION-AF trial results for the Watchman device, while positive, fell short of market expectations. Analysts now await Q1 2026 earnings to assess whether EP performance can rebound and ease concerns over long-term growth durability.
Shares have underperformed amid broader skepticism, with hedge funds reducing exposure to the stock in early 2026.